Guardion Health Sciences (GHSI) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 05, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-38861
Entity Registrant Name	GUARDION HEALTH SCIENCES, INC.
Entity Central Index Key	0001642375
Entity Tax Identification Number	47-4428421
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2925 Richmond Avenue
Entity Address, Address Line Two	Suite 1200
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77098
City Area Code	800
Local Phone Number	873-5141
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	GHSI
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		61,600,823

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 12,946,003	$ 4,093,927
Short-term investments		4,995,623
Accounts receivable, net	1,873,743	1,411,567
Inventories	1,952,931	367,691
Prepaid expenses	1,038,439	1,200,376
Total current assets	17,811,116	12,069,184
Property and equipment, net	53,763	111,378
Intangible assets, net	10,363,333	11,255,833
Operating lease right-of-use asset, net		24,257
Total assets	28,228,212	23,460,652
Current liabilities
Accounts payable	1,040,596	241,347
Accrued expenses	683,158	895,477
Operating lease liability - current	9,472	22,221
Total current liabilities	1,733,226	1,159,045
Operating lease liability – long-term		3,807
Total liabilities	1,733,226	1,162,852
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2022 and December 31, 2021
Common stock, $0.001 par value; 250,000,000 shares authorized; 61,600,823 shares and 24,426,993 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	61,601	24,427
Additional paid-in capital	111,252,019	101,075,445
Accumulated deficit	(84,818,634)	(78,802,072)
Total stockholders’ equity	26,494,986	22,297,800
Total liabilities and stockholders’ equity	$ 28,228,212	$ 23,460,652

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	61,600,823	24,426,993
Common stock, shares outstanding	61,600,823	24,426,993

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue
Total revenue	$ 2,663,550	$ 3,148,612	$ 8,323,382	$ 4,605,628
Cost of goods sold
Total cost of goods sold	1,575,366	1,760,586	4,739,197	2,558,840
Gross profit	1,088,184	1,388,026	3,584,185	2,046,788
Operating expenses
Research and development	60,203	16,234	162,418	53,598
Sales and marketing	526,193	777,526	1,583,349	1,754,321
General and administrative	2,231,895	3,297,725	7,875,894	8,048,713
Transaction costs related to acquisition				2,103,680
Impairment of right-of-use asset		280,176	24,257	280,176
Loss on disposal of fixed assets	9,287	31,883	9,287	31,883
Total operating expenses	2,827,578	4,403,544	9,655,205	12,272,371
Loss from operations	(1,739,394)	(3,015,518)	(6,071,020)	(10,225,583)
Other income (expense):
Interest income, net	43,282	682	54,458	934
Net loss	$ (1,696,112)	$ (3,014,836)	$ (6,016,562)	$ (10,224,649)
Net loss per common share - basic and diluted	$ (0.03)	$ (0.12)	$ (0.11)	$ (0.44)
Weighted average common shares outstanding – basic and diluted	61,600,823	24,426,993	54,196,178	23,413,055
Clinical Nutrition [Member]
Revenue
Total revenue	$ 2,663,550	$ 3,109,525	$ 8,304,663	$ 4,443,113
Cost of goods sold
Total cost of goods sold	1,575,366	1,730,318	4,739,197	2,454,423
Other [Member]
Revenue
Total revenue		39,087	18,719	162,515
Cost of goods sold
Total cost of goods sold		$ 30,268		$ 104,417

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 15,171	$ 62,583,423	$ (54,083,328)	$ 8,515,266
Beginning Balance, shares at Dec. 31, 2020	15,170,628
Fair value of vested stock options		205,772		205,772
Fair value of vested restricted stock		181,843		181,843
Common stock issued for cash, net of offering costs	$ 7,608	33,654,989		33,662,597
Common stock issued for cash, net of offering costs, shares	7,608,674
Common stock issued upon exercise of warrants	$ 1,648	3,566,767		3,568,415
Common stock issued upon exercise of warrants, shares	1,647,691
Net loss			(2,669,525)	(2,669,525)
Cumulative adjustment due to adoption of ASU 2020-06			26,265	26,265
Ending balance, value at Mar. 31, 2021	$ 24,427	100,192,794	(56,726,588)	43,490,633
Ending balance, shares at Mar. 31, 2021	24,426,993
Beginning balance, value at Dec. 31, 2020	$ 15,171	62,583,423	(54,083,328)	8,515,266
Beginning Balance, shares at Dec. 31, 2020	15,170,628
Net loss				(10,224,649)
Ending balance, value at Sep. 30, 2021	$ 24,427	100,900,334	(64,281,712)	36,643,049
Ending balance, shares at Sep. 30, 2021	24,426,993
Beginning balance, value at Mar. 31, 2021	$ 24,427	100,192,794	(56,726,588)	43,490,633
Beginning Balance, shares at Mar. 31, 2021	24,426,993
Fair value of vested stock options		183,452		183,452
Fair value of vested restricted stock		159,640		159,640
Net loss			(4,540,288)	(4,540,288)
Ending balance, value at Jun. 30, 2021	$ 24,427	100,535,886	(61,266,876)	39,293,437
Ending balance, shares at Jun. 30, 2021	24,426,993
Fair value of vested stock options		200,005		200,005
Net loss			$ (3,014,836)	$ (3,014,836)
Common stock issued for services		164,443		164,443
Ending balance, value at Sep. 30, 2021	$ 24,427	$ 100,900,334	$ (64,281,712)	$ 36,643,049
Ending balance, shares at Sep. 30, 2021	24,426,993
Beginning balance, value at Dec. 31, 2021	$ 24,427	101,075,445	(78,802,072)	22,297,800
Beginning Balance, shares at Dec. 31, 2021	24,426,993
Fair value of vested stock options		85,963		85,963
Fair value of vested restricted stock		59,906		59,906
Common stock issued for cash, net of offering costs	$ 32,550	8,802,349		8,834,899
Common stock issued for cash, net of offering costs, shares	32,550,000
Common stock issued upon exercise of warrants	$ 4,450	1,129,590		1,134,040
Common stock issued upon exercise of warrants, shares	4,450,000
Net loss			(2,618,487)	(2,618,487)
Ending balance, value at Mar. 31, 2022	$ 61,427	111,153,253	(81,420,559)	29,794,121
Ending balance, shares at Mar. 31, 2022	61,426,993
Beginning balance, value at Dec. 31, 2021	$ 24,427	101,075,445	(78,802,072)	22,297,800
Beginning Balance, shares at Dec. 31, 2021	24,426,993
Net loss				(6,016,562)
Ending balance, value at Sep. 30, 2022	$ 61,601	111,252,019	(84,818,634)	26,494,986
Ending balance, shares at Sep. 30, 2022	61,600,823
Beginning balance, value at Mar. 31, 2022	$ 61,427	111,153,253	(81,420,559)	29,794,121
Beginning Balance, shares at Mar. 31, 2022	61,426,993
Fair value of vested stock options		61,818		61,818
Fair value of vested restricted stock		11,585		11,585
Net loss			(1,701,963)	(1,701,963)
Issuance of vested restricted stock, net of shares withheld for payment of employee withholding tax	$ 174	(24,185)		(24,011)
Issuance of vested restricted stock, net of shares withheld for payment of employee withholding tax, shares	173,830
Ending balance, value at Jun. 30, 2022	$ 61,601	111,202,471	(83,122,522)	28,141,550
Ending balance, shares at Jun. 30, 2022	61,600,823
Fair value of vested stock options		44,101		44,101
Fair value of vested restricted stock		5,447		5,447
Net loss			(1,696,112)	(1,696,112)
Ending balance, value at Sep. 30, 2022	$ 61,601	$ 111,252,019	$ (84,818,634)	$ 26,494,986
Ending balance, shares at Sep. 30, 2022	61,600,823

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating Activities
Net loss	$ (6,016,562)	$ (10,224,649)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	946,397	457,782
Loss on disposal of fixed assets	9,287	31,883
Impairment of right-of-use asset	24,257	280,176
Fair value of vested stock options	191,882	589,229
Fair value of vested restricted common stock	76,938	505,926
(Increase) decrease in:
Accounts receivable, net	(41,679)	(457,680)
Inventories	(1,585,240)	205,401
Prepaid expenses	(258,560)	(1,017,755)
Operating lease right-of-use asset		119,579
Increase (decrease) in:
Accounts payable	799,249	260,911
Operating lease liability	(16,556)	(120,839)
Accrued expenses	(212,319)	440,822
Payable to former officer		(148,958)
Net cash used in operating activities	(6,082,906)	(9,078,172)
Investing Activities
Purchase of property and equipment	(5,569)	(76,809)
Purchase of US Treasury Bills	(77,591,741)	(62,975,823)
Sale of US Treasury Bills	82,587,364	55,981,015
Cash paid for acquisition; net of cash acquired		(26,036,102)
Net cash provided by (used in) investing activities	4,990,054	(33,107,719)
Financing Activities
Proceeds from sale of common stock, net	8,834,899	33,662,599
Proceeds from exercise of warrants	1,134,040	3,568,414
Payment for employee withholding tax	(24,011)
Net cash provided by financing activities	9,944,928	37,231,013
Cash and cash equivalents:
Net increase (decrease) in cash and cash equivalents	8,852,076	(4,954,878)
Balance at beginning of period	4,093,927	8,518,732
Balance at end of period	12,946,003	3,563,854
Cash paid for:
Income taxes		20,844
Interest
Non-cash financing activities:
Adjust warrant liability for adoption of ASU 2020-06		$ 25,978

Organization and Business Opera

Organization and Business Operations	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Operations	1. Organization and Business Operations Business Guardion Health Sciences, Inc., a Delaware corporation (the “Company”), was incorporated in June 2015, and is currently headquartered in Houston, Texas. The Company develops and distributes clinically supported nutritional medical foods and dietary supplements. These products are designed to support retail consumers, healthcare professionals and providers, and their patients by strengthening bone health and immune health to guard the body from the forces of aging though a scientifically developed combination of Calcium, Vitamin D, and Vitamin K. On June 1, 2021, the Company acquired Activ Nutritional, LLC (“Activ”), the owner and distributor of the Viactiv® line of supplements for bone health and other applications (see Note 3). As a result of the Activ acquisition, the Company’s commercial efforts fundamentally changed to its current focus on science-based clinical nutrition and supplements. Liquidity The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. For the nine months ended September 30, 2022, the Company incurred a net loss of $ 6,016,562 6,082,906 12,946,003 16,077,890 Notwithstanding the net loss for the nine months ended September 30, 2022, management believes that its current cash as of September 30, 2022 is sufficient to ensure continuation of the Company as a going concern for at least one year from the date of this Quarterly Report on Form 10-Q. The amount and timing of future cash requirements will depend, in part, on the Company’s ability to ultimately achieve operating profitability. The Company expects to continue to incur net losses and negative operating cash flows in the near-term and will continue to incur significant expenses for the development, commercialization and distribution of its clinical nutrition products and the successful development and commercialization of any new products or product lines. The Company may also utilize cash to fund acquisitions or other strategic initiatives. The Company may seek to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms, or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its product development programs and/or curtail or cease its operations. COVID-19 and Inflation COVID-19 and Supply Disruptions Inflation. Nasdaq Notice On January 25, 2022, the Company received a written notice from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company had not been in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for a period of 30 consecutive business days. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum closing bid price of $ 1.00 In accordance with Nasdaq Listing Rule 5810(3)(A), the Company was provided a compliance period of 180 calendar days from the date of the notice, or until July 25, 2022, to regain compliance with the $1.00 minimum bid price requirement. The Company did not regain compliance during the compliance period ended July 25, 2022. Accordingly, the Company requested that Nasdaq grant the Company a second 180 calendar day period to regain compliance. On July 26, 2022, the Company received a written notice from Nasdaq that the Company was granted a second 180 calendar day period, or until January 23, 2023, to regain compliance with the $ 1.00 minimum bid price requirement. Nasdaq’s determination to grant the second compliance period was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the minimum bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. Previously, at the Company’s Annual Meeting of Stockholders (“Annual Meeting”) held on June 16, 2022, the proposal to grant discretionary authority to the Company’s Board Directors 1-for-30 split, with the exact ratio to be determined by the Board of Directors in its sole discretion (the “Reverse Stock Split”) was not approved by the requisite vote of a majority of the Company’s issued and outstanding shares. Although 63% of the stockholders represented at the Annual Meeting voted in favor of the Reverse Stock Split, more than 50% of the Company’s issued and outstanding shares were required to vote in favor of the at least $ 1.00 per share for a minimum of 10 consecutive business days prior to January 23, 2023. The Company is carefully assessing potential actions to regain compliance, including, without limitation, holding a special stockholders’ meeting to solicit approval of a Reverse Stock Split; however, the Company may be unable to regain compliance with the $ 1.00 If the Company fails to regain compliance during the second 180-day period that will expire on January 23, 2023, then Nasdaq will notify the Company of its determination to delist the Company’s common stock, at which point the Company will have an opportunity to appeal the delisting determination to the Hearing Review Council at Nasdaq , before the Company’s common stock is formally delisted

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. The unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial statements for the year ended December 31, 2021 and, in the opinion of management, reflect all adjustments, which consist of normal recurring adjustments, considered necessary for a fair presentation of the periods presented. The results of operations for the interim periods presented are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2022. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes, included in the Company’s 2021 Annual Report on Form 10-K, filed with the SEC on March 31, 2022. The condensed consolidated balance sheet as of December 31, 2021, was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation. For the year ended December 31, 2021, management concluded that the Company had one operating and reporting segment made up of its clinical nutrition business, and management changed the Company’s reportable segments to align with these revisions to the Company’s internal reporting structure. The Company previously had two reportable segments, which included a clinical nutrition segment and a medical devices segment. At September 30 , 2022 and December 31, 2021, as there was only one Reverse Stock Split On March 1, 2021, the Company effectuated a one-for-six (1:6) reverse stock split Use of Estimates The preparation of the Company’s financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. On an ongoing basis, management reviews its estimates and, if deemed appropriate, those estimates are adjusted. Significant estimates include those related to assumptions used in valuing inventories at net realizable value, assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets, assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ materially from those estimates. Revenue Recognition The Company recognizes revenue and costs of sales when control of the products transfers to the customer, which generally occurs upon delivery to the customer. The Company’s performance obligations are satisfied upon delivery to the customer. All products sold by the Company are distinct individual products and are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from products. The Company does not have any significant contracts with customers requiring performance beyond delivery, and contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Historically, the Company has not experienced any significant payment delays from customers. Due to the insignificant amount of historical returns, as well as the standalone nature of the Company’s products, and the assessment of performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly basis. Revenues by geographical area are as follows: Schedule of Revenue by Geographical Area 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 North America $ 2,663,550 $ 3,132,782 $ 8,304,483 $ 4,481,439 Asia - 29,584 - 117,633 Europe and other - (13,754 ) 18,899 6,556 Total revenue $ 2,663,550 $ 3,148,612 $ 8,323,382 $ 4,605,628 Third-Party Outsourcing The Company derives substantially all of its revenue from the sale of products using a third-party fulfillment center to provide order processing and sales fulfillment, customer invoicing and collections, and product warehousing. Substantially all of the Company’s products are shipped through the third-party fulfillment center to the customer. Shipping charges to customers are included in revenues. In addition, the Company uses the third-party fulfillment center to provide sales and inventory management, and marketing and promotional services. The Company outsources the production of substantially all of its products with a third-party that manufactures and packages the finished products under a product supply agreement. Costs incurred related to third-party outsourcing, which includes manufacturing, order processing and fulfillment, customer invoicing, collections and warehousing, were approximately $ 1,876,259 4,951,259 1,932,967 2,560,487 Cost of Goods Sold Cost of goods sold is comprised of the costs for third-party contract manufacturing, packaging, manufacturing fees, and in-bound freight charges. Shipping Costs Shipping costs associated with product distribution after manufacture are included as part of cost of goods sold. Shipping and handling expense totaled $ 209,804 182,580 622,178 277,997 Advertising Costs Advertising costs are expensed as incurred and are included in sales and marketing expense. Advertising costs were $ 385,010 513,701 1,264,740 1,203,421 Concentrations Revenue. 57 49 10 10 , During the nine months ended September 30, 2022, the Company had one customer that accounted for 56 42 10 10 , Accounts receivable September 30, 2022 , the Company had accounts receivable from one customer which comprised approximately 63 , the Company had accounts receivable from two customers which comprised approximately 50 48 10 and December 31, 2021. Historically the Company has not experienced any collectability issues with this customer. Purchases from vendors three months and nine months ended September 30, 2022 , the Company utilized one manufacturer for most of its production and packaging of its clinical nutrition products. Total purchases from this manufacturer accounted for approximately 49 , 2022 that accounted for 12 , the Company’s largest vendor accounted for approximately 38 16 15 10 and 2021. Accounts payable September 30, 2022 , one vendor accounted for 88 the Company’s largest two vendors accounted for 18 13 10 and December 31, 2021. Cash and cash equivalents Cash and cash equivalents consist of funds deposited with a major, established, high quality financial institution and short-term (original maturity of generally 60 days or less) liquid investments in money market deposit accounts. Cash equivalents are classified as Level 1 in the GAAP valuation hierarchy and are valued using the net asset value (“NAV”) per share of the money market fund. As of September 30, 2022, included in cash and cash equivalents was $ 12,917,044 The Company’s policy is to maintain its cash balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the “FDIC”) and/or by the Securities Investor Protection Corporation (the “SIPC”). The Company may periodically have cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $250,000 and $500,000, respectively. The Company has not experienced any losses to date resulting from this policy, and management believes that the risk of loss associated with any uninsured balances is remote. Investments Short-term investments held by the Company as of December 31, 2021 consist of a U.S. Treasury Bill, which is classified as held-to-maturity. The Company’s U.S. Treasury Bill was scheduled to mature approximately 30 days from the date of purchase. Unrealized gains and losses were not material. As of December 31, 2021, the carrying value of the Company’s U.S. Treasury Bill approximates its fair value due to its short-term maturity. As of September 30, 2022, the Company held no short-term investments. Intangible Assets Amortizable finite-lived identifiable intangible assets consist of a trade name and customer relationships acquired in the acquisition of Activ, effective June 1, 2021 (See Note 3), and are stated at cost less accumulated amortization. The trade name and customer relationships are being amortized over a period of 10 At September 30, 2022, management concluded that there were no impairment triggering events. If economic uncertainty increases and/or the global economy worsens, the Company’s business, financial condition and results of operations may be sufficiently impacted to result in future impairment charges in the short-term. Management will continue to monitor the effects that macroeconomic conditions have on its business and operations, and will review impairment indicators to the extent necessary in the upcoming months. Stock-Based Compensation Stock-based awards for stock options and restricted stock awards to employees and non-employees are accounted using the fair value method in accordance with ASC 718 , Share-Compensation – Stock Compensation Loss per Common Share Basic loss per share is computed by dividing net loss by the weighted-average common shares outstanding during the period, excluding shares of unvested restricted common stock outstanding. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Shares of vested restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are vested. Dilutive potential common shares include shares from unexercised warrants and options. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive. The Company’s basic and diluted net loss per share is the same for all periods presented as the Company had a net loss for all periods presented and all shares issuable upon exercise of warrants and options would therefore be anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 September 30, 2022 2021 Warrants 74,485,067 485,067 Options 723,510 1,019,762 Unvested restricted common stock 33,333 - Anti-dilutive securities excluded from computation of earnings per share 75,241,910 1,504,829 Fair Value of Financial Instruments Accounting standards require certain assets and liabilities be reported at fair value in the financial statements and provide a framework for establishing that fair value. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation techniques used to measure fair value: Level 1 – Level 2 – Level 3 – The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The following table sets forth by level, within the fair value hierarchy, the Company’s financial assets at fair value as of September 30, 2022 and December 31, 2021: Schedule of Financial Assets at Fair Value Level 1 Level 2 Level 3 Total September 30, 2022 Level 1 Level 2 Level 3 Total Assets U.S. Treasury securities $ - $ - $ - $ - Total assets $ - $ - $ - $ - Level 1 Level 2 Level 3 Total December 31, 2021 Level 1 Level 2 Level 3 Total Assets U.S. Treasury securities $ 4,995,623 - - 4,995,623 Total assets $ 4,995,623 $ - $ - $ 4,995,623 The Company believes the carrying amount of its financial instruments (consisting of cash, short-term investments, accounts receivable, accounts payable and accrued liabilities) approximates fair value due to the short-term nature of such instruments. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) . At December 31, 2020, the Company recorded a derivative liability of $ 26,265 10,417 26,265 26,265 In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options Recently Issued Accounting Pronouncements Not Yet Adopted In September 2016, the FASB issued ASU No. 2016-13, Credit Losses – Measurement of Credit Losses on Financial Instruments Other recent accounting pronouncements issued by FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Acquisition of Activ Nutritiona

Acquisition of Activ Nutritional, LLC	9 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Acquisition of Activ Nutritional, LLC	3. Acquisition of Activ Nutritional, LLC On June 1, 2021, the Company acquired Activ, the owner and distributor of the Viactiv® line of supplements for bone health and other applications, for total purchase consideration of $ 25,949,654 The following table summarizes the allocation of the fair value of the purchase consideration to the fair value of tangible assets, identifiable intangible assets, and assumed liabilities of Activ on the date of acquisition: Schedule of Fair Value of Assets Acquired and Liabilities Assumed Fair value of consideration: Purchase price, as adjusted, paid in cash $ 25,949,654 Allocation of the consideration to the fair value of assets acquired and liabilities assumed: Net tangible assets 2,156,520 Trade names and trademarks 9,200,000 Customer relationships 2,700,000 Net identifiable intangible assets 11,900,000 Goodwill 11,893,134 Fair value of net assets acquired $ 25,949,654 The Company consolidated Activ’s operations with the Company’s operations commencing on June 1, 2021. Subsequently, goodwill of $ 11,893,134 Activ’s revenue and operating income (loss) included in the accompanying condensed consolidated statements of operations are as follows: Schedule of Activ’s Revenue and Operating Income (Loss) 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenue $ 2,563,398 $ 2,998,117 $ 8,006,229 $ 4,047,920 Operating income (loss) (38,598 ) 496,621 155,974 727,909 Pro Forma Information The following unaudited pro forma condensed consolidated statement of operations for the three months and nine months ended September 30, 2021 is presented as if the acquisition of Activ had occurred on January 1, 2021, and after giving effect to certain pro forma adjustments. The pro forma condensed consolidated statement of operations is presented for informational purposes only and is not indicative of the results of operations that would have necessarily been achieved if the acquisition had actually been consummated on January 1, 2021. Schedule of Pro Forma Financial Information Three Months Ended Nine Months Ended Revenue $ 3,148,612 $ 10,138,421 Net loss $ (3,014,836 ) $ (7,726,233 ) Net loss per share – basic and diluted $ (0.12 ) $ (0.31 ) Acquisition-related transaction costs of $ 2,103,680

Inventories

Inventories	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Inventories	4. Inventories Inventories consisted of the following on the dates noted below: Schedule of Inventories September 30, December 31, 2022 2021 Raw materials $ 49,699 $ 53,320 Finished goods 1,903,232 314,371 Inventory $ 1,952,931 $ 367,691 The Company’s inventories are stated at the lower of cost or net realizable value calculated on a first-in, first-out basis.

Property and Equipment, Net

Property and Equipment, Net	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	5. Property and Equipment, Net Property and equipment, net consisted of the following on the dates noted below: Schedule of Property and Equipment September 30, December 31, 2022 2021 Furniture and fixtures $ 110,175 $ 129,696 Computer equipment and software 66,115 111,469 Other - 6,540 Property, Plant and Equipment, Gross 176,290 247,705 Less accumulated depreciation and amortization (122,527 ) (136,327 ) Property, Plant and Equipment, Net $ 53,763 $ 111,378 Depreciation expense for the three months ended September 30, 2022 and 2021 was $ 14,717 20,008 53,897 61,115 50,923 41,636 9,287

Intangible Assets, Net

Intangible Assets, Net	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	6. Intangible Assets, Net Intangible assets, net consisted of the following on the dates noted below: Schedule of Intangible Assets September 30, December 31, 2022 2021 Trade name $ 9,200,000 $ 9,200,000 Customer relationships 2,700,000 2,700,000 Trademark 50,000 50,000 Intangible assets, gross 11,950,000 11,950,000 Less accumulated amortization (1,586,667 ) (694,167 ) Intangible assets, net $ 10,363,333 $ 11,255,833 Amortizable finite-lived identifiable intangible assets consist of a trade name and customer relationships acquired in the acquisition of Activ, effective as of June 1, 2021 (see Note 3), and are being amortized over a period of 10 For the three months and nine months ended September 30, 2022, amortization expense was $ 297,500 892,500 297,500 396,667 Schedule of Finite-lived Intangible Assets Amortization Expense Total 2022 (remaining 3 months) $ 297,500 2023 1,190,000 2024 1,190,000 2025 1,190,000 2026 1,190,000 Thereafter 5,255,832 Total future expected amortization expense $ 10,313,332

Operating Leases

Operating Leases	9 Months Ended
	Sep. 30, 2022
Operating Leases
Operating Leases	7. Operating Leases At September 30, 2022, the Company leased its primary corporate office space located in Houston, Texas, under a month-to-month lease with a lease payment of approximately $ 2,200 1,900 During the three months ended September 30, 2022 and 2021, rent expense totaled $ 6,884 44,548 22,991 132,002 As of December 31, 2021, the Company’s right-of-use asset related to its warehouse space totaled $ 24,257 24,257 0 As of December 31, 2021, the Company’s operating lease liability related to its warehouse space totaled $ 26,028 16,556 9,472 As of September 30, 2022, the remaining lease term related to the warehouse space was 5 months, and the discount rate for the warehouse space lease is 3.9 Future minimum lease payments under the leases are as follows: Schedule of Lease Liability Year ending Operating Lease 2022 (remaining 3 months) $ 5,739 2023 3,826 Total lease payments 9,565 Less: Imputed interest/present value discount (93 ) Present value of lease liabilities 9,472 Less: Current portion (9,472 ) Operating Lease Liability Noncurrent $ -

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders’ Equity	8. Stockholders’ Equity Common Stock February 2022 Offering On February 18, 2022, the Company entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company issued and sold, (i) 32,550,000 0.30 0.37 0.37 4,450,000 0.2999 0.0001 The exercise prices of the Series A Warrants and Series B Warrants are subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company’s common stock. In addition, in the event the Company effects a reverse stock split during the term of the Series A Warrants and Series B Warrants, the exercise price of such warrants following such reverse split will be subject to further adjustment in the event the trading price of our common stock following such reverse stock split is lower than the exercise price of such warrants. Also, subject to customary exceptions, the exercise price of the Series A Warrants is subject to adjustment in the event of issuances of the Company’s common stock or common stock equivalents at a price below the exercise price of the Series A Warrants. In such event, the exercise price of the Series A Warrants will be reduced to the price of the securities issued in such transactions. In the event of a fundamental transaction, the holder of a warrant shall have the option, exercisable at any time concurrently with, or within 30 days after, the consummation of the fundamental transaction to cause the Company to purchase such warrant from the holder for cash in an amount equal to the Black Scholes value of such warrant calculated in accordance with the terms of warrant. On February 18, 2022, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with Roth Capital Partners LLC (“Roth”) and Maxim Group LLC, as co agents (collectively, the “Agents”), pursuant to which the Company paid the Agents an aggregate fee equal to 7.0 100,000 1,850,000 0.37 On February 23, 2022, the Company closed the February 2022 Offering, and issued (i) 32,550,000 37,000,000 37,000,000 4,450,000 11,100,000 9,969,000 1,134,000 January 2021 At the Market Offerings In January 2021, the Company entered into two sales agreements pursuant to which the Company could sell up to $ 35,000,000 3.0 7,608,674 35,000,000 33,662,597 Warrants A summary of the Company’s warrant activity is as follows: Schedule of Warrants Activity Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) December 31, 2021 485,067 $ 2.71 2.46 Granted 78,450,000 0.37 2.75 Forfeitures - - - Expirations - - - Exercised (4,450,000 ) - - September 30, 2022, all exercisable 74,485,067 $ 0.38 2.74 The exercise prices of warrants outstanding and exercisable as of September 30, 2022 are as follows: Schedule of Exercise Price of Warrants Outstanding and Exercisable Warrants Outstanding and Exercisable (Shares) Exercise Prices 74,000,000 $ 0.37 160.108 2.05 146,667 2.67 112,001 3.30 37,700 3.51 18,174 17.25 10,417 30.00 74,485,067 During the nine months ended September 30, 2022, and in connection with the February 2022 Offering described above, investors exercised warrants to purchase 4,450,000 0.2999 1,334,555 1,134,040 Stock Options A summary of the Company’s stock option activity is as follows: Schedule of Share-based Compensation, Stock Options, Activity Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) December 31, 2021 853,088 $ 6.34 6.5 Granted 66,668 0.15 5 Forfeitures (100,102 ) - Expirations (96,144 ) 12.00 - Exercised - - - September 30, 2022, outstanding 723,510 5.26 6.2 September 30, 2022, exercisable 540,552 - = The exercise prices of options outstanding and exercisable as of September 30, 2022 are as follows: Schedule of Exercise Price of Options Outstanding and Exercisable Options Outstanding (Shares) Options Exercisable (Shares) Exercise Prices 66,668 16,672 $ 0.15 41,667 28,645 0.91 50,000 16,667 1.61 50,000 31,245 1.76 41,667 41,667 2.33 16,667 16,667 3.25 152,671 84,819 3.95 191,670 191,670 6.00 112,500 112,500 15.00 723,510 540,552 During the nine months ended September 30, 2022, the Company granted options to purchase an aggregate of 66,668 7,793 146 0 zero 3 0.15 8,336 two years During the nine months ended September 30, 2021, the Company granted options to purchase 269,339 shares of common stock to the Company’s employees and to the independent members of the Board of Directors with a grant date fair value of $ 652,360 using a Black-Scholes option pricing model based on the following assumptions: (i) volatility rates of 117 % to 119 %, (ii) a discount rate of 0.38 % to 1.28 %, (iii) zero expected dividend yield, and (iv) an expected life of 6 years. The options have an exercise price of $ 1.61 to $ 3.95 per share. 67,558 of the options vested on the one-year anniversary of the grant date, 135,113 of the options will vest on monthly basis over two years , and 66,668 of the options will , subject to continued service As described above, as 16,333 shares of the Company’s common stock on June 30, 2021. The Company computes stock price volatility over expected terms based on its historical common stock trading prices. The risk-free interest rate was based on rates established by the Federal Reserve Bank. The expected dividend yield was based on the fact that the Company has not paid dividends to its common stockholders in the past and does not expect to pay dividends to its common stockholders in the future. The expected life of the stock options granted is estimated using the “simplified” method, whereby the expected term equals the average of the vesting term and the original contractual term of the stock option. For the nine months ended September 30, 2022 and 2021, the Company recognized aggregate stock-compensation expense of $ 191,882 589,229 As of September 30, 2022, the Company had an aggregate of 182,958 321,331 5 0.14 0 Restricted Common Stock During the nine months ended September 30, 2022, there were no grants of restricted shares of Company common stock. During the nine months ended September 30, 2022, approximately 211,005 37,145 24,011 During the nine months ended September 30, 2021, the Company granted 244,338 152,671 41,667 50,000 three years The total fair value of the 244,338 742,911 76,938 505,926 24,892 1.75 The following table summarizes restricted common stock activity for the nine months ended September 30, 2022: Schedule of Non Vested Restricted Common Stock Activity Number of shares Fair value of shares Non-vested shares, December 31, 2021 202,671 $ 3.37 Granted - - Vested (169,338 ) 3.72 Forfeited - - Non-vested shares, September 30, 2022 33,333 1.61 2018 Equity Incentive Plan In 2018, the Company’s stockholders originally approved the 2018 Equity Incentive Plan (as amended, the “2018 Plan”). Under the 2018 Plan (as amended, as described below), up to 10,000,000 1,666,666 10,000,000 10,000,000 66,668 202,671 152,671 50,000 66,668 202,671 152,671 50,000 As of September 30, 2022, the Company has granted 611,007 202,671 9,186,322

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Legal Proceedings In the normal course of business, the Company is periodically the subject of various pending or threatened legal actions and claims arising out of its operations. At September 30, 2022 and December 31, 2021, the Company was not a party to any material legal proceedings and is not aware of any pending or threatened legal proceedings against the Company that it believes could have a material adverse effect on its business, operating results, cash flows or financial condition.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events The Company performed an evaluation of subsequent events through the date of filing of these condensed consolidated financial statements with the SEC. There were no material subsequent events which affected, or could affect, the amounts or disclosures in the condensed consolidated financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. The unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual financial statements for the year ended December 31, 2021 and, in the opinion of management, reflect all adjustments, which consist of normal recurring adjustments, considered necessary for a fair presentation of the periods presented. The results of operations for the interim periods presented are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2022. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes, included in the Company’s 2021 Annual Report on Form 10-K, filed with the SEC on March 31, 2022. The condensed consolidated balance sheet as of December 31, 2021, was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All inter-company transactions and balances have been eliminated in consolidation. For the year ended December 31, 2021, management concluded that the Company had one operating and reporting segment made up of its clinical nutrition business, and management changed the Company’s reportable segments to align with these revisions to the Company’s internal reporting structure. The Company previously had two reportable segments, which included a clinical nutrition segment and a medical devices segment. At September 30 , 2022 and December 31, 2021, as there was only one
Reverse Stock Split	Reverse Stock Split On March 1, 2021, the Company effectuated a one-for-six (1:6) reverse stock split
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. On an ongoing basis, management reviews its estimates and, if deemed appropriate, those estimates are adjusted. Significant estimates include those related to assumptions used in valuing inventories at net realizable value, assumptions used in valuing assets acquired in business acquisitions, impairment testing of goodwill and other long-term assets, assumptions used in valuing stock-based compensation, the valuation allowance for deferred tax assets, accruals for potential liabilities, and assumptions used in the determination of the Company’s liquidity. Actual results could differ materially from those estimates.
Revenue Recognition	Revenue Recognition The Company recognizes revenue and costs of sales when control of the products transfers to the customer, which generally occurs upon delivery to the customer. The Company’s performance obligations are satisfied upon delivery to the customer. All products sold by the Company are distinct individual products and are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from products. The Company does not have any significant contracts with customers requiring performance beyond delivery, and contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Historically, the Company has not experienced any significant payment delays from customers. Due to the insignificant amount of historical returns, as well as the standalone nature of the Company’s products, and the assessment of performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly basis. Revenues by geographical area are as follows: Schedule of Revenue by Geographical Area 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 North America $ 2,663,550 $ 3,132,782 $ 8,304,483 $ 4,481,439 Asia - 29,584 - 117,633 Europe and other - (13,754 ) 18,899 6,556 Total revenue $ 2,663,550 $ 3,148,612 $ 8,323,382 $ 4,605,628 Third-Party Outsourcing The Company derives substantially all of its revenue from the sale of products using a third-party fulfillment center to provide order processing and sales fulfillment, customer invoicing and collections, and product warehousing. Substantially all of the Company’s products are shipped through the third-party fulfillment center to the customer. Shipping charges to customers are included in revenues. In addition, the Company uses the third-party fulfillment center to provide sales and inventory management, and marketing and promotional services. The Company outsources the production of substantially all of its products with a third-party that manufactures and packages the finished products under a product supply agreement. Costs incurred related to third-party outsourcing, which includes manufacturing, order processing and fulfillment, customer invoicing, collections and warehousing, were approximately $ 1,876,259 4,951,259 1,932,967 2,560,487
Cost of Goods Sold	Cost of Goods Sold Cost of goods sold is comprised of the costs for third-party contract manufacturing, packaging, manufacturing fees, and in-bound freight charges.
Shipping Costs	Shipping Costs Shipping costs associated with product distribution after manufacture are included as part of cost of goods sold. Shipping and handling expense totaled $ 209,804 182,580 622,178 277,997
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred and are included in sales and marketing expense. Advertising costs were $ 385,010 513,701 1,264,740 1,203,421
Concentrations	Concentrations Revenue. 57 49 10 10 , During the nine months ended September 30, 2022, the Company had one customer that accounted for 56 42 10 10 , Accounts receivable September 30, 2022 , the Company had accounts receivable from one customer which comprised approximately 63 , the Company had accounts receivable from two customers which comprised approximately 50 48 10 and December 31, 2021. Historically the Company has not experienced any collectability issues with this customer. Purchases from vendors three months and nine months ended September 30, 2022 , the Company utilized one manufacturer for most of its production and packaging of its clinical nutrition products. Total purchases from this manufacturer accounted for approximately 49 , 2022 that accounted for 12 , the Company’s largest vendor accounted for approximately 38 16 15 10 and 2021. Accounts payable September 30, 2022 , one vendor accounted for 88 the Company’s largest two vendors accounted for 18 13 10 and December 31, 2021.
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents consist of funds deposited with a major, established, high quality financial institution and short-term (original maturity of generally 60 days or less) liquid investments in money market deposit accounts. Cash equivalents are classified as Level 1 in the GAAP valuation hierarchy and are valued using the net asset value (“NAV”) per share of the money market fund. As of September 30, 2022, included in cash and cash equivalents was $ 12,917,044 The Company’s policy is to maintain its cash balances with financial institutions with high credit ratings and in accounts insured by the Federal Deposit Insurance Corporation (the “FDIC”) and/or by the Securities Investor Protection Corporation (the “SIPC”). The Company may periodically have cash balances in financial institutions in excess of the FDIC and SIPC insurance limits of $250,000 and $500,000, respectively. The Company has not experienced any losses to date resulting from this policy, and management believes that the risk of loss associated with any uninsured balances is remote.
Investments	Investments Short-term investments held by the Company as of December 31, 2021 consist of a U.S. Treasury Bill, which is classified as held-to-maturity. The Company’s U.S. Treasury Bill was scheduled to mature approximately 30 days from the date of purchase. Unrealized gains and losses were not material. As of December 31, 2021, the carrying value of the Company’s U.S. Treasury Bill approximates its fair value due to its short-term maturity. As of September 30, 2022, the Company held no short-term investments.
Intangible Assets	Intangible Assets Amortizable finite-lived identifiable intangible assets consist of a trade name and customer relationships acquired in the acquisition of Activ, effective June 1, 2021 (See Note 3), and are stated at cost less accumulated amortization. The trade name and customer relationships are being amortized over a period of 10 At September 30, 2022, management concluded that there were no impairment triggering events. If economic uncertainty increases and/or the global economy worsens, the Company’s business, financial condition and results of operations may be sufficiently impacted to result in future impairment charges in the short-term. Management will continue to monitor the effects that macroeconomic conditions have on its business and operations, and will review impairment indicators to the extent necessary in the upcoming months.
Stock-Based Compensation	Stock-Based Compensation Stock-based awards for stock options and restricted stock awards to employees and non-employees are accounted using the fair value method in accordance with ASC 718 , Share-Compensation – Stock Compensation
Loss per Common Share	Loss per Common Share Basic loss per share is computed by dividing net loss by the weighted-average common shares outstanding during the period, excluding shares of unvested restricted common stock outstanding. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Shares of vested restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are vested. Dilutive potential common shares include shares from unexercised warrants and options. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive. The Company’s basic and diluted net loss per share is the same for all periods presented as the Company had a net loss for all periods presented and all shares issuable upon exercise of warrants and options would therefore be anti-dilutive. The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 September 30, 2022 2021 Warrants 74,485,067 485,067 Options 723,510 1,019,762 Unvested restricted common stock 33,333 - Anti-dilutive securities excluded from computation of earnings per share 75,241,910 1,504,829
Fair Value of Financial Instruments	Fair Value of Financial Instruments Accounting standards require certain assets and liabilities be reported at fair value in the financial statements and provide a framework for establishing that fair value. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. When determining fair value, the Company considers the principal or most advantageous market in which it transacts and considers assumptions that market participants would use when pricing the asset or liability. The framework for determining fair value is based on a hierarchy that prioritizes the inputs and valuation techniques used to measure fair value: Level 1 – Level 2 – Level 3 – The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The following table sets forth by level, within the fair value hierarchy, the Company’s financial assets at fair value as of September 30, 2022 and December 31, 2021: Schedule of Financial Assets at Fair Value Level 1 Level 2 Level 3 Total September 30, 2022 Level 1 Level 2 Level 3 Total Assets U.S. Treasury securities $ - $ - $ - $ - Total assets $ - $ - $ - $ - Level 1 Level 2 Level 3 Total December 31, 2021 Level 1 Level 2 Level 3 Total Assets U.S. Treasury securities $ 4,995,623 - - 4,995,623 Total assets $ 4,995,623 $ - $ - $ 4,995,623 The Company believes the carrying amount of its financial instruments (consisting of cash, short-term investments, accounts receivable, accounts payable and accrued liabilities) approximates fair value due to the short-term nature of such instruments.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) . At December 31, 2020, the Company recorded a derivative liability of $ 26,265 10,417 26,265 26,265 In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options Recently Issued Accounting Pronouncements Not Yet Adopted In September 2016, the FASB issued ASU No. 2016-13, Credit Losses – Measurement of Credit Losses on Financial Instruments Other recent accounting pronouncements issued by FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Revenue by Geographical Area	Revenues by geographical area are as follows: Schedule of Revenue by Geographical Area 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 North America $ 2,663,550 $ 3,132,782 $ 8,304,483 $ 4,481,439 Asia - 29,584 - 117,633 Europe and other - (13,754 ) 18,899 6,556 Total revenue $ 2,663,550 $ 3,148,612 $ 8,323,382 $ 4,605,628
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	The following potentially dilutive shares were excluded from the shares used to calculate diluted earnings per share: Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share 2022 2021 September 30, 2022 2021 Warrants 74,485,067 485,067 Options 723,510 1,019,762 Unvested restricted common stock 33,333 - Anti-dilutive securities excluded from computation of earnings per share 75,241,910 1,504,829
Schedule of Financial Assets at Fair Value	The following table sets forth by level, within the fair value hierarchy, the Company’s financial assets at fair value as of September 30, 2022 and December 31, 2021: Schedule of Financial Assets at Fair Value Level 1 Level 2 Level 3 Total September 30, 2022 Level 1 Level 2 Level 3 Total Assets U.S. Treasury securities $ - $ - $ - $ - Total assets $ - $ - $ - $ - Level 1 Level 2 Level 3 Total December 31, 2021 Level 1 Level 2 Level 3 Total Assets U.S. Treasury securities $ 4,995,623 - - 4,995,623 Total assets $ 4,995,623 $ - $ - $ 4,995,623

Acquisition of Activ Nutritio_2

Acquisition of Activ Nutritional, LLC (Tables)	9 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Fair Value of Assets Acquired and Liabilities Assumed	The following table summarizes the allocation of the fair value of the purchase consideration to the fair value of tangible assets, identifiable intangible assets, and assumed liabilities of Activ on the date of acquisition: Schedule of Fair Value of Assets Acquired and Liabilities Assumed Fair value of consideration: Purchase price, as adjusted, paid in cash $ 25,949,654 Allocation of the consideration to the fair value of assets acquired and liabilities assumed: Net tangible assets 2,156,520 Trade names and trademarks 9,200,000 Customer relationships 2,700,000 Net identifiable intangible assets 11,900,000 Goodwill 11,893,134 Fair value of net assets acquired $ 25,949,654
Schedule of Activ’s Revenue and Operating Income (Loss)	Schedule of Activ’s Revenue and Operating Income (Loss) 2022 2021 2022 2021 Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenue $ 2,563,398 $ 2,998,117 $ 8,006,229 $ 4,047,920 Operating income (loss) (38,598 ) 496,621 155,974 727,909
Schedule of Pro Forma Financial Information	Schedule of Pro Forma Financial Information Three Months Ended Nine Months Ended Revenue $ 3,148,612 $ 10,138,421 Net loss $ (3,014,836 ) $ (7,726,233 ) Net loss per share – basic and diluted $ (0.12 ) $ (0.31 )

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following on the dates noted below: Schedule of Inventories September 30, December 31, 2022 2021 Raw materials $ 49,699 $ 53,320 Finished goods 1,903,232 314,371 Inventory $ 1,952,931 $ 367,691

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consisted of the following on the dates noted below: Schedule of Property and Equipment September 30, December 31, 2022 2021 Furniture and fixtures $ 110,175 $ 129,696 Computer equipment and software 66,115 111,469 Other - 6,540 Property, Plant and Equipment, Gross 176,290 247,705 Less accumulated depreciation and amortization (122,527 ) (136,327 ) Property, Plant and Equipment, Net $ 53,763 $ 111,378

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets, net consisted of the following on the dates noted below: Schedule of Intangible Assets September 30, December 31, 2022 2021 Trade name $ 9,200,000 $ 9,200,000 Customer relationships 2,700,000 2,700,000 Trademark 50,000 50,000 Intangible assets, gross 11,950,000 11,950,000 Less accumulated amortization (1,586,667 ) (694,167 ) Intangible assets, net $ 10,363,333 $ 11,255,833
Schedule of Finite-lived Intangible Assets Amortization Expense	Schedule of Finite-lived Intangible Assets Amortization Expense Total 2022 (remaining 3 months) $ 297,500 2023 1,190,000 2024 1,190,000 2025 1,190,000 2026 1,190,000 Thereafter 5,255,832 Total future expected amortization expense $ 10,313,332

Operating Leases (Tables)

Operating Leases (Tables)	9 Months Ended
	Sep. 30, 2022
Operating Leases
Schedule of Lease Liability	Future minimum lease payments under the leases are as follows: Schedule of Lease Liability Year ending Operating Lease 2022 (remaining 3 months) $ 5,739 2023 3,826 Total lease payments 9,565 Less: Imputed interest/present value discount (93 ) Present value of lease liabilities 9,472 Less: Current portion (9,472 ) Operating Lease Liability Noncurrent $ -

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of Warrants Activity	A summary of the Company’s warrant activity is as follows: Schedule of Warrants Activity Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) December 31, 2021 485,067 $ 2.71 2.46 Granted 78,450,000 0.37 2.75 Forfeitures - - - Expirations - - - Exercised (4,450,000 ) - - September 30, 2022, all exercisable 74,485,067 $ 0.38 2.74
Schedule of Exercise Price of Warrants Outstanding and Exercisable	The exercise prices of warrants outstanding and exercisable as of September 30, 2022 are as follows: Schedule of Exercise Price of Warrants Outstanding and Exercisable Warrants Outstanding and Exercisable (Shares) Exercise Prices 74,000,000 $ 0.37 160.108 2.05 146,667 2.67 112,001 3.30 37,700 3.51 18,174 17.25 10,417 30.00 74,485,067
Schedule of Share-based Compensation, Stock Options, Activity	A summary of the Company’s stock option activity is as follows: Schedule of Share-based Compensation, Stock Options, Activity Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term (Years) December 31, 2021 853,088 $ 6.34 6.5 Granted 66,668 0.15 5 Forfeitures (100,102 ) - Expirations (96,144 ) 12.00 - Exercised - - - September 30, 2022, outstanding 723,510 5.26 6.2 September 30, 2022, exercisable 540,552 - =
Schedule of Exercise Price of Options Outstanding and Exercisable	The exercise prices of options outstanding and exercisable as of September 30, 2022 are as follows: Schedule of Exercise Price of Options Outstanding and Exercisable Options Outstanding (Shares) Options Exercisable (Shares) Exercise Prices 66,668 16,672 $ 0.15 41,667 28,645 0.91 50,000 16,667 1.61 50,000 31,245 1.76 41,667 41,667 2.33 16,667 16,667 3.25 152,671 84,819 3.95 191,670 191,670 6.00 112,500 112,500 15.00 723,510 540,552
Schedule of Non Vested Restricted Common Stock Activity	The following table summarizes restricted common stock activity for the nine months ended September 30, 2022: Schedule of Non Vested Restricted Common Stock Activity Number of shares Fair value of shares Non-vested shares, December 31, 2021 202,671 $ 3.37 Granted - - Vested (169,338 ) 3.72 Forfeited - - Non-vested shares, September 30, 2022 33,333 1.61

Organization and Business Ope_2

Organization and Business Operations (Details Narrative) - USD ($)			3 Months Ended						9 Months Ended
	Jul. 26, 2022	Mar. 01, 2021	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Jan. 25, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss			$ 1,696,112	$ 1,701,963	$ 2,618,487	$ 3,014,836	$ 4,540,288	$ 2,669,525	$ 6,016,562	$ 10,224,649
Net cash used in operating activities									6,082,906	$ 9,078,172
Cash and short-term investments			12,946,003						12,946,003
Working capital			$ 16,077,890						$ 16,077,890
Minimum closing bid price	$ 1										$ 1
Stockholders' Equity, Reverse Stock Split	1-for-30	one-for-six (1:6) reverse stock split

Schedule of Revenue by Geograph

Schedule of Revenue by Geographical Area (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Total revenue	$ 2,663,550	$ 3,148,612	$ 8,323,382	$ 4,605,628
North America [Member]
Total revenue	2,663,550	3,132,782	8,304,483	4,481,439
Asia [Member]
Total revenue		29,584		117,633
Europe And Other [Member]
Total revenue		$ (13,754)	$ 18,899	$ 6,556

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	75,241,910	1,504,829
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	74,485,067	485,067
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	723,510	1,019,762
Unvested Restricted Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of earnings per share	33,333

Schedule of Financial Assets at

Schedule of Financial Assets at Fair Value (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Total assets		$ 4,995,623
US Treasury Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total assets		4,995,623
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total assets		4,995,623
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total assets		4,995,623
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total assets
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total assets
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Total assets
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Total assets

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative)				3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 26, 2022	Jun. 01, 2021	Mar. 01, 2021	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) Segment	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) Segment	Dec. 31, 2020 USD ($)	Dec. 31, 2019 shares
Product Information [Line Items]
Number of Reporting Units | Segment						1		1
Stockholders' equity, reverse stock split	1-for-30		one-for-six (1:6) reverse stock split
Third party outsourcing				$ 1,876,259	$ 4,951,259	$ 1,932,967	$ 2,560,487
Cost of goods sold				1,575,366	1,760,586	4,739,197	2,558,840
Advertising Expense				385,010	$ 513,701	1,264,740	$ 1,203,421
Cash Equivalents, at Carrying Value				12,917,044		12,917,044
Intangible asset, useful life		10 years
Derivative liability									$ 26,265
Accumulated deficit				$ (84,818,634)		$ (84,818,634)		$ (78,802,072)
Accounting Standards Update 2020-06 [Member]
Product Information [Line Items]
Accumulated deficit									26,265
Decrease in derivative warrant liability									$ 26,265
Warrant [Member]
Product Information [Line Items]
Number of warrants issued | shares										10,417
Trade Name And Customer Relationships [Member]
Product Information [Line Items]
Intangible asset, useful life						10 years
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk, percentage				57%	49%	56%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Customer [Member]
Product Information [Line Items]
Concentration risk, percentage					10%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Other Customers [Member] | Minimum [Member]
Product Information [Line Items]
Concentration risk, percentage				10%	10%	10%	10%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration risk, percentage							42%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Product Information [Line Items]
Concentration risk, percentage							10%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | One Customer [Member]
Product Information [Line Items]
Concentration risk, percentage						63%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Other Customers [Member] | Minimum [Member]
Product Information [Line Items]
Concentration risk, percentage						10%		10%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]
Product Information [Line Items]
Concentration risk, percentage								50%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]
Product Information [Line Items]
Concentration risk, percentage								48%
Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | One Manufacturer [Member]
Product Information [Line Items]
Concentration risk, percentage				49%
Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Other Vendor [Member]
Product Information [Line Items]
Concentration risk, percentage				12%
Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Other Vendor [Member] | Minimum [Member]
Product Information [Line Items]
Concentration risk, percentage				10%	10%	10%	10%
Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Vendor [Member]
Product Information [Line Items]
Concentration risk, percentage					38%
Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Vendor One [Member]
Product Information [Line Items]
Concentration risk, percentage							16%
Cost of Goods and Service Benchmark [Member] | Supplier Concentration Risk [Member] | Vendor Two [Member]
Product Information [Line Items]
Concentration risk, percentage							15%
Accounts Payable [Member] | Customer Concentration Risk [Member] | Other Vendor [Member] | Minimum [Member]
Product Information [Line Items]
Concentration risk, percentage						10%		10%
Accounts Payable [Member] | Customer Concentration Risk [Member] | Vendor One [Member]
Product Information [Line Items]
Concentration risk, percentage								18%
Accounts Payable [Member] | Customer Concentration Risk [Member] | Vendor Two [Member]
Product Information [Line Items]
Concentration risk, percentage								13%
Accounts Payable [Member] | Customer Concentration Risk [Member] | One Vendor [Member]
Product Information [Line Items]
Concentration risk, percentage						88%
Shipping and Handling [Member]
Product Information [Line Items]
Cost of goods sold				$ 209,804	$ 182,580	$ 622,178	$ 277,997

Schedule of Fair Value of Asset

Schedule of Fair Value of Assets Acquired and Liabilities Assumed (Details) - Activ Nutritional, LLC [Member] - USD ($)	Jun. 01, 2021	Dec. 31, 2021
Business Acquisition [Line Items]
Purchase price, as adjusted, paid in cash	$ 25,949,654
Net tangible assets	2,156,520
Net identifiable intangible assets	11,900,000
Goodwill	11,893,134	$ 11,893,134
Fair value of net assets acquired	25,949,654
Trademarks and Trade Names [Member]
Business Acquisition [Line Items]
Net identifiable intangible assets	9,200,000
Customer Relationships [Member]
Business Acquisition [Line Items]
Net identifiable intangible assets	$ 2,700,000

Schedule of Activ_s Revenue and

Schedule of Activ’s Revenue and Operating Income (Loss) (Details) - Activ Nutritional, LLC [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Business Acquisition [Line Items]
Revenue	$ 2,563,398	$ 2,998,117	$ 8,006,229	$ 4,047,920
Operating income (loss)	$ (38,598)	$ 496,621	$ 155,974	$ 727,909

Schedule of Pro Forma Financial

Schedule of Pro Forma Financial Information (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]
Revenue	$ 3,148,612	$ 10,138,421
Net loss	$ (3,014,836)	$ (7,726,233)
Net loss per share – basic and diluted	$ (0.12)	$ (0.31)

Acquisition of Activ Nutritio_3

Acquisition of Activ Nutritional, LLC (Details Narrative) - Activ Nutritional, LLC [Member] - USD ($)	Jun. 01, 2021	Sep. 30, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Purchase consideration	$ 25,949,654
Goodwill	$ 11,893,134		$ 11,893,134
Acquisition transaction cost		$ 2,103,680

Schedule of Inventories (Detail

Schedule of Inventories (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 49,699	$ 53,320
Finished goods	1,903,232	314,371
Inventory	$ 1,952,931	$ 367,691

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 176,290	$ 247,705
Less accumulated depreciation and amortization	(122,527)	(136,327)
Property, Plant and Equipment, Net	53,763	111,378
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	110,175	129,696
Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	66,115	111,469
Other [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross		$ 6,540

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 14,717	$ 20,008	$ 53,897	$ 61,115
Cost of depreciated assets			50,923
Removal of depreciation			41,636
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property	$ 9,287	$ 31,883	$ 9,287	$ 31,883

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Trade name	$ 9,200,000	$ 9,200,000
Customer relationships	2,700,000	2,700,000
Trademark	50,000	50,000
Intangible assets, gross	11,950,000	11,950,000
Less accumulated amortization	(1,586,667)	(694,167)
Intangible assets, net	$ 10,363,333	$ 11,255,833

Schedule of Finite-lived Intang

Schedule of Finite-lived Intangible Assets Amortization Expense (Details)	Sep. 30, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2022 (remaining 3 months)	$ 297,500
2023	1,190,000
2024	1,190,000
2025	1,190,000
2026	1,190,000
Thereafter	5,255,832
Total future expected amortization expense	$ 10,313,332

Intangible Assets, Net (Details

Intangible Assets, Net (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Jun. 01, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization period	10 years
Amortization of Intangible Assets		$ 297,500	$ 297,500	$ 892,500	$ 396,667

Schedule of Lease Liability (De

Schedule of Lease Liability (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Operating Leases
2022 (remaining 3 months)	$ 5,739
2023	3,826
Total lease payments	9,565
Less: Imputed interest/present value discount	(93)
Present value of lease liabilities	9,472	$ 26,028
Less: Current portion	(9,472)	(22,221)
Operating Lease Liability Noncurrent		$ 3,807

Operating Leases (Details Narra

Operating Leases (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Rent expense	$ 6,884	$ 44,548	$ 22,991	$ 132,002
Right of use asset					$ 24,257
Impairment of right of use asset		$ 280,176	24,257	$ 280,176
Operating lease liabilities	$ 9,472		9,472		$ 26,028
Operating lease payments			$ 16,556
Lease discount rate	3.90%		3.90%
Houston, Texas [Member]
Operating lease payments, per month			$ 2,200
Greenville, Ohio [Member]
Operating lease payments, per month			$ 1,900

Schedule of Warrants Activity (

Schedule of Warrants Activity (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Ending Balance	74,485,067
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares, Beginning Balance	485,067
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 2.71
Weighted Average Remaining Contractual Term Years, Beginning Balance	2 years 5 months 15 days
Shares, Granted	78,450,000
Weighted Average Exercise Price, Granted | $ / shares	$ 0.37
Weighted Average Remaining Contractual Term Years Granted	2 years 9 months
Shares, Forfeitures
Weighted Average Exercise Price, Forfeitures | $ / shares
Shares, Expirations
Weighted Average Exercise Price, Expirations | $ / shares
Shares, Exercised	(4,450,000)
Weighted Average Exercise Price, Exercised | $ / shares
Shares, Ending Balance	74,485,067
Weighted Average Exercise Price, Ending Balance | $ / shares	$ 0.38
Weighted Average Remaining Contractual Term Years, Ending Balance	2 years 8 months 26 days

Schedule of Exercise Price of W

Schedule of Exercise Price of Warrants Outstanding and Exercisable (Details)	Sep. 30, 2022 $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	74,485,067
Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	74,000,000
Exercise Prices | $ / shares	$ 0.37
Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	160.108
Exercise Prices | $ / shares	$ 2.05
Warrant Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	146,667
Exercise Prices | $ / shares	$ 2.67
Warrant Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	112,001
Exercise Prices | $ / shares	$ 3.30
Warrant Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	37,700
Exercise Prices | $ / shares	$ 3.51
Warrant Six [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	18,174
Exercise Prices | $ / shares	$ 17.25
Warrant Seven [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants Outstanding and Exercisable (Shares)	10,417
Exercise Prices | $ / shares	$ 30

Schedule of Share-based Compens

Schedule of Share-based Compensation, Stock Options, Activity (Details) - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Equity [Abstract]
Shares Outstanding, Beginning Balance	853,088
Weighted Average Exercise Price Outstanding, Beginning Balance	$ 6.34
Weighted Average Remaining Contractual Term Years Outstanding, Beginning Balance	6 years 6 months
Shares, Granted	66,668
Weighted Average Exercise Price, Granted	$ 0.15
Weighted Average Remaining Contractual Term Years Outstanding, Granted	5 years
Shares, Forfeitures	(100,102)
Shares, Expirations	(96,144)
Weighted Average Exercise Price, Expirations	$ 12
Shares, Exercised
Weighted Average Exercise Price, Exercised
Shares Outstanding, Ending Balance	723,510	66,668
Weighted Average Exercise Price Outstanding, Ending Balance	$ 5.26
Weighted Average Remaining Contractual Term Years Outstanding, Ending Balance	6 years 2 months 12 days
Shares Exercisable, Ending Balance	540,552

Schedule of Exercise Price of O

Schedule of Exercise Price of Options Outstanding and Exercisable (Details) - $ / shares	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	723,510	853,088	66,668
Options Exercisable (Shares)	540,552
Exercise Price One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	66,668
Options Exercisable (Shares)	16,672
Exercise Prices	$ 0.15
Exercise Price Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	41,667
Options Exercisable (Shares)	28,645
Exercise Prices	$ 0.91
Exercise Price Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	50,000
Options Exercisable (Shares)	16,667
Exercise Prices	$ 1.61
Exercise Price Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	50,000
Options Exercisable (Shares)	31,245
Exercise Prices	$ 1.76
Exercise Price Five [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	41,667
Options Exercisable (Shares)	41,667
Exercise Prices	$ 2.33
Exercise Price Six [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	16,667
Options Exercisable (Shares)	16,667
Exercise Prices	$ 3.25
Exercise Price Seven [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	152,671
Options Exercisable (Shares)	84,819
Exercise Prices	$ 3.95
Exercise Price Eight [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	191,670
Options Exercisable (Shares)	191,670
Exercise Prices	$ 6
Exercise Price Nine [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	112,500
Options Exercisable (Shares)	112,500
Exercise Prices	$ 15

Schedule of Non Vested Restrict

Schedule of Non Vested Restricted Common Stock Activity (Details) - Restricted Common Stock [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares, Non-vested shares, beginning | shares	202,671
Fair value of shares, Non-vested shares, beginning | $ / shares	$ 3.37
Number of shares, Granted | shares
Fair value of shares, Granted | $ / shares
Number of shares, Vested | shares	(169,338)
Fair value of shares, Vested | $ / shares	$ 3.72
Number of shares, Forfeited | shares
Number of shares, Forfeited | $ / shares
Number of shares, Non-vested shares, ending | shares	33,333
Number of shares, Non-vested shares, ending | $ / shares	$ 1.61

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)					1 Months Ended	3 Months Ended		9 Months Ended
	Sep. 16, 2022	Sep. 15, 2022	Feb. 23, 2022	Feb. 18, 2022	Jan. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Expenses						$ 2,827,578	$ 4,403,544	$ 9,655,205	$ 12,272,371
Proceeds from warrant exercises								1,134,040	3,568,414
Proceeds from issuance of common stock								$ 8,834,899	$ 33,662,599
Stock options, grants								66,668
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number						723,510	66,668	723,510	66,668	853,088
Stock Options [Member]
Subsidiary, Sale of Stock [Line Items]
Share-based payment arrangement, expense								$ 191,882	$ 589,229
Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Grant date fair value of options granted								742,911
Share-based payment arrangement, expense								$ 76,938	$ 505,926
Number of shares restricted stock, gross								211,005
Share based compensation vested net. issued								37,145
Share - based compensation withholding obligation amount								24,011
Number of restricted stock issued									244,338
Fair value of shares								244,338
Unvested compensation award						$ 24,892		$ 24,892
Unvested options, amortized year								1 year 9 months
2018 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Stock options, grants								611,007
Number of restricted stock issued								202,671
Employee stock ownership plan (ESOP), plan description								In 2018, the Company’s stockholders originally approved the 2018 Equity Incentive Plan (as amended, the “2018 Plan”). Under the 2018 Plan (as amended, as described below), up to 10,000,000 shares of common stock may be granted to employees, directors and consultants in the form of stock options, restricted stock units and other stock-based awards.
Board of Directors [Member]
Subsidiary, Sale of Stock [Line Items]
Stock options, grants								66,668
Grant date fair value of options granted								$ 7,793
Volatility rate								146%
Discount rate								0%
Expected dividend yield								0%	0%
Expected life								3 years	6 years
Stock option, exercise price per share								$ 0.15
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number							135,113		135,113
Board of Directors [Member] | 2018 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Stock options, grants								66,668	66,668
Board of Directors [Member] | Vested One Year [Member]
Subsidiary, Sale of Stock [Line Items]
Number of options vested								8,336	67,558
Board of Directors [Member] | Vest On Quarterly Basis [Member]
Subsidiary, Sale of Stock [Line Items]
Vesting period								2 years	2 years
Chief Executive Officer [Member]
Subsidiary, Sale of Stock [Line Items]
Stock options, grants									269,339
Grant date fair value of options granted									$ 652,360
Chief Executive Officer [Member] | Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of restricted stock issued									152,671
Chief Executive Officer [Member] | 2018 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Number of restricted stock issued									152,671
Five Non Officer Directors [Member]
Subsidiary, Sale of Stock [Line Items]
Stock options, grants									16,333
Consultant [Member] | Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Number of restricted stock issued									41,667
Chief Commercial Officer [Member] | Restricted Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Vesting period									3 years
Number of restricted stock issued									50,000
Chief Commercial Officer [Member] | 2018 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Stock options, grants									50,000
Number of restricted stock issued									50,000
Employees Directors And Consultant [Member] | 2018 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued	10,000,000	1,666,666						10,000,000
Number of shares issued (Increase and decrease)								10,000,000
Chief Exective Officer [Member] | 2018 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Stock options, grants									152,671
Maximum [Member] | Board of Directors [Member]
Subsidiary, Sale of Stock [Line Items]
Volatility rate									117%
Discount rate									0.38%
Stock option, exercise price per share									$ 3.95
Minimum [Member] | Board of Directors [Member]
Subsidiary, Sale of Stock [Line Items]
Volatility rate									119%
Discount rate									1.28%
Stock option, exercise price per share									$ 1.61
Unvested Options [Member]
Subsidiary, Sale of Stock [Line Items]
Number of unvested options outstanding						182,958		182,958
Number of unvested options outstanding, value						$ 321,331		$ 321,331
Unvested options, weighted average remaining life								5 years
Closing stock price						$ 0.14		$ 0.14
Aggregate intrinsic value of options outstanding						$ 0		$ 0
Common Stock [Member] | 2018 Plan [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares restricted stock, gross									202,671
Number of shares purchased for issuance									202,671
Number of shares available for grants						9,186,322		9,186,322
February 2022 Offering [Member] | Warrants [Member] | Investors [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares issued								4,450,000
Proceeds from warrant exercises								$ 1,134,040
Stock price						$ 0.2999		$ 0.2999
Gross proceeds from warrants								$ 1,334,555
February 2022 Offering [Member] | Securities Purchase Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock sold			32,550,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			4,450,000
Proceeds from Issuance Initial Public Offering			$ 11,100,000
Number of share issued transaction			9,969,000
Proceeds from warrant exercises			$ 1,134,000
February 2022 Offering [Member] | Securities Purchase Agreement [Member] | Series A Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock sold			37,000,000	32,550,000
Per share unit				$ 0.30
warrant exercise price				0.37
warrant exercise price				$ 0.37
February 2022 Offering [Member] | Securities Purchase Agreement [Member] | Series B Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock sold			37,000,000	4,450,000
Per share unit				$ 0.2999
warrant exercise price				$ 0.0001
February 2022 Offering [Member] | Placement Agency Agreement [Member] | Roth Capital Partners LLC [Member]
Subsidiary, Sale of Stock [Line Items]
Number of share issued transaction				7%
Expenses				$ 100,000
Number of shares issued				1,850,000
common stock exercise price				$ 0.37
January 2021 ATM Offerings [Member] | Sales Agreement [Member]
Subsidiary, Sale of Stock [Line Items]
Number of stock sold					7,608,674
Percentage of shares sold					3%
Gross proceeds from issuance of common stock					$ 35,000,000
Proceeds from issuance of common stock					33,662,597
January 2021 ATM Offerings [Member] | Sales Agreement [Member] | Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock					$ 35,000,000